No phaseRecruiting
Study on the Management of COMISA (COMISA-PEC)
- Sponsor
- University Hospital, Grenoble (Academic or other)
- Enrolment
- 150 planned
- Conditions
- Obstructive Sleep Apnea (OSA); Insomnia; COMISA
- Interventions
- Daridorexant 50 mg; Continuous Positive Air Pressure (CPAP)
- Ages
- adults, older adults
- Registry
- NCT07743931
From the registry
COMISA, the combination of obstructive sleep apnea (OSA) and insomnia, is a frequent and burdensome condition. Many patients with OSA experience clinically significant insomnia symptoms, and a substantial proportion of individuals with chronic insomnia also meet criteria for OSA. This comorbidity is associated with more severe symptoms, more complex diagnostic pathways, and reduced adherence to continuous positive airway pressure (CPAP) therapy. This study aims to better understand COMISA and evaluate whether adding daridorexant to CPAP treatment can improve treatment adherence and overall patient outcomes.
Primary outcomes
- To evaluate, in patients diagnosed with COMISA and treated with CPAP, the impact of daridorexant on CPAP adherence at 4 months compared with patients not receiving daridorexant.